论文部分内容阅读
目的 :观察硫普罗宁 (凯西莱 )在乳癌化疗轻度肝损害患者中的保肝作用。方法 :对56例乳癌选用CMF方案 ,患者随机分为治疗组和对照组。治疗组28例加凯西莱静滴及口服 ,28例患者为对照组用肌苷静滴及口服 ,观察一周期化疗后ALT的变化 ,结果治疗组化疗后ALT值显著低于化疗前组 ,与对照组比较差异有显著性。结论 :对乳癌化疗轻度肝损伤患者凯西莱可对抗化疗性肝损害 ,改善肝脏功能 ,保证化疗连续性
Objective: To observe the hepatoprotective effects of tiopronin (Kesilai) in patients with mild hepatic impairment induced by breast cancer chemotherapy. Methods: 56 cases of breast cancer selection CMF program, patients were randomly divided into treatment group and control group. In the treatment group, 28 cases were treated with Caesaril intravenously and 28 cases were treated with inosine infusion and oral administration. The changes of ALT after one-cycle chemotherapy were observed. The results showed that ALT in the treatment group was significantly lower than that in the chemotherapy group, Compared with the control group, the difference was significant. Conclusion: Kesilai can prevent chemotherapy-induced liver damage, improve liver function and ensure chemotherapy continuity in breast cancer patients with mild liver injury